220 related articles for article (PubMed ID: 15142195)
1. Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status.
Trebble TM; Wootton SA; Stroud MA; Mullee MA; Calder PC; Fine DR; Moniz C; Arden NK
Aliment Pharmacol Ther; 2004 May; 19(10):1063-71. PubMed ID: 15142195
[TBL] [Abstract][Full Text] [Related]
2. Immune activation and nutritional status in adult Crohn's disease patients.
Reimund JM; Arondel Y; Escalin G; Finck G; Baumann R; Duclos B
Dig Liver Dis; 2005 Jun; 37(6):424-31. PubMed ID: 15893281
[TBL] [Abstract][Full Text] [Related]
3. High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial.
Trebble TM; Stroud MA; Wootton SA; Calder PC; Fine DR; Mullee MA; Moniz C; Arden NK
Br J Nutr; 2005 Aug; 94(2):253-61. PubMed ID: 16115360
[TBL] [Abstract][Full Text] [Related]
4. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.
Ryan BM; Russel MG; Schurgers L; Wichers M; Sijbrandij J; Stockbrugger RW; Schoon E
Aliment Pharmacol Ther; 2004 Oct; 20(8):851-7. PubMed ID: 15479356
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood mononuclear cell fatty acid composition and inflammatory mediator production in adult Crohn's disease.
Trebble TM; Arden NK; Wootton SA; Mullee MA; Calder PC; Burdge GC; Fine DR; Stroud MA
Clin Nutr; 2004 Aug; 23(4):647-55. PubMed ID: 15297102
[TBL] [Abstract][Full Text] [Related]
6. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
7. Oral butyrate for mildly to moderately active Crohn's disease.
Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant and immune status in active Crohn's disease. A possible relationship.
Reimund JM; Hirth C; Koehl C; Baumann R; Duclos B
Clin Nutr; 2000 Feb; 19(1):43-8. PubMed ID: 10700533
[TBL] [Abstract][Full Text] [Related]
9. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease.
Karoui S; Ouerdiane S; Serghini M; Jomni T; Kallel L; Fekih M; Boubaker J; Filali A
Dig Liver Dis; 2007 Nov; 39(11):1006-10. PubMed ID: 17889628
[TBL] [Abstract][Full Text] [Related]
10. Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease.
Saverymuttu SH; Peters AM; Lavender JP; Pepys MB; Hodgson HJ; Chadwick VS
Gastroenterology; 1983 Dec; 85(6):1333-9. PubMed ID: 6628930
[TBL] [Abstract][Full Text] [Related]
11. Altered subjective appetite parameters in Crohn's disease patients.
Bannerman E; Davidson I; Conway C; Culley D; Aldhous MC; Ghosh S
Clin Nutr; 2001 Oct; 20(5):399-405. PubMed ID: 11534934
[TBL] [Abstract][Full Text] [Related]
12. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
13. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
[TBL] [Abstract][Full Text] [Related]
14. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
[TBL] [Abstract][Full Text] [Related]
15. [Assay of trace elements in the serum by the PIXE method in patients with Crohn's disease].
Deflandre J; Weber G; Delbrouck JM; Roelandts I; Robaye G; Brassinne A
Gastroenterol Clin Biol; 1985 Oct; 9(10):719-25. PubMed ID: 2998916
[TBL] [Abstract][Full Text] [Related]
16. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
17. Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy.
Tobias JH; Sasi MR; Greenwood R; Probert CS
Aliment Pharmacol Ther; 2004 Nov; 20(9):951-7. PubMed ID: 15521842
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
19. Increased serum bone sialoprotein concentrations in patients with Crohn's disease.
Faust D; Menge F; Armbruster FP; Lembcke B; Stein J
Z Gastroenterol; 2003 Mar; 41(3):243-7. PubMed ID: 12664344
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha haplotype is strongly associated with bone mineral density in patients with Crohn's disease.
Lee N; Fowler E; Mason S; Lincoln D; Taaffe DR; Radford-Smith G
J Gastroenterol Hepatol; 2007 Jun; 22(6):913-9. PubMed ID: 17565648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
